ROIV Valuation

Roivant Sciences Ltd

Add to Watchlist

Advanced Chart

11.550

+0.17(1.494%)1D

Overview
Forecast
Valuation
Earnings

ROIV Relative Valuation

ROIV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ROIV is overvalued; if below, it's undervalued.

Historical Valuation

Roivant Sciences Ltd (ROIV) is now in the Overvalued zone, suggesting that its current forward PS ratio of 265.75 is considered Overvalued compared with the five-year average of -7.10. The fair price of Roivant Sciences Ltd (ROIV) is between 0.71 to 4.65 according to relative valuation methord. Compared to the current price of 11.38 USD , Roivant Sciences Ltd is Overvalued By 144.56%.

Relative Value

Fair Zone

0.71-4.65

Current Price：11.38

144.56%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.69

P/B

Median3y

3.71

Median5y

3.02

-10.80

FCF Yield

Median3y

-12.79

Median5y

-31.31

Competitors Valuation Multiple

The average P/S ratio for ROIV's competitors is 48.36, providing a benchmark for relative valuation. Roivant Sciences Ltd Corp (ROIV) exhibits a P/S ratio of 265.75, which is 449.57% above the industry average. Given its robust revenue growth of -16.08%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap